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ABSTRACT
Objective: To evaluate the impact of  the use of  topical Mupirocin on the insertion of  central venous catheter for hemodialysis. Methods: This 
was a systematic review with meta-analysis. Results: After a careful and extensive search, we included three clinical trials that compared the 
use of  Mupirocin versus other intervention in central venous catheter for hemodialysis. Conclusion: The study found that the use of  topical 
Mupirocin is effective in reducing episodes of  infection among hemodialysis patients, increasing duration time for catheter, and significantly 
reducing S aureus infections, which are the most prevalent in this population.
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RESUMO 
Objetivo: Avaliar o impacto do uso de Mupirocina tópica em inserção de cateter venoso central para hemodiálise. Métodos: Revisão Sistemática 
com Metanálise. Resultados: Após uma criteriosa e extensa busca, foram incluídos três ensaios clínicos que compararam o uso de Mupirocina 
versus outra intervenção em cateter venoso central para hemodiálise. Conclusão: O estudo apontou que o uso de Mupirocina tópica é eficaz 
para redução dos episódios de infecções entre os pacientes em hemodiálise, aumentando o tempo de utilização do cateter, além de reduzir 
significativamente as infecções por S aureus as mais prevalentes nessa população.
Descritores: Hemodiálise; Cateterismo venoso central; Mupirocina; S aureus; Metanálise
RESUMEN
Objetivo: Evaluar el impacto del uso de Mupirocina tópica en inserción de cateter venoso central para hemodiálisis. Métodos: Revisión Sistemática 
con Metaanálisis. Resultados: Después de una criteriosa y extensa búsqueda, se incluyeron tres ensayos clínicos que compararon el uso de 
Mupirocina versus otra intervención en cateter venoso central para hemodiálise. Conclusión: El estudio demostró que el uso de Mupirocina 
tópica es eficaz para la reducción de los episodios de infecciones entre los pacientes en hemodiálisis, aumentando el tiempo de utilización del 
cateter, además de reducir significativamente las infecciones por S aureus, las más prevalentes en esa población.
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INTRODUCTION
In hemodialysis, central venous catheters (CVC) 
provide a rapid and temporary access alternative for 
the establishment of  treatment in patients with acute 
or terminal kidney disease. The use of  CVCs should be 
quite limited due to the frequent occurrence of  blood-
stream infection; as shown in several studies, the rate is 
approximately 40% (1–7).
Infection is the second leading cause of  mortality 
among patients with end stage renal disease (ESRD) and 
represents, approximately, 14% of  deaths among these 
individuals, preceded only by cardiovascular events (8).
According to the National Census of  the Brazilian 
Society of  Nephrology, the number of  patients on di-
alysis treatment in Brazil, in 2007, was 73,605; and, of  
these, 90.8%, received hemodialysis (9).
Patients receiving hemodialysis have a high risk of  
infection due to the immunosuppressive effects caused 
by ESRD, comorbidities, inadequate nutrition and 
the need for maintenance of  vascular access for long 
periods. In dialysis centers, many patients are undergo-
ing hemodialysis simultaneously, which facilitates the 
spread of  microorganisms by direct or indirect contact 
through the devices, equipment, surface contact, and 
hands of  health professionals (4,10). However, the qual-
ity of  dialysis and, consequently, the well-being and 
survival of  the patient depend on vascular access; on 
the other hand, it is considered the major risk factor 
for infection, and particularly, of  bacteremia in this 
patient population (11). 
Central venous access is considered a less suit-
able alternative in relation to arteriovenous fistula, as 
recommended by K/DOQI (Kidney Disease Outcome 
Quality Initiative) (12). Despite the recommendations of  
the Dialysis Outcomes and Practice Patterns Study (DOPPS 
II), studies show that the use of  CVC for hemodialysis 
among patients in Europe and Canada varies between 
46% to 70% of  these patients. The high use of  CVC 
for hemodialysis may reflect: a delayed search for a ne-
phrologist, initiation of  therapy in emergency situations, 
patients with diabetes and major vascular compromise, 
and lack of  experience on the part of  professionals in 
inserting a fistula (13-15). 
A study conducted at the Federal University of  São 
Paulo showed a bacteremia incidence of  61% among 
patients with ESRD when using CVC. Risk factors for 
developing bacteremia were: implantation of  a catheter 
into the subclavian vein, length of  time catheter was in 
place, and length of  hospitalization. The mortality rate 
in these patients was 29%, and for those who progressed 
to endocarditis, the mortality rate was 55.5%(16).
The rate of  infection related to CVC for hemodialy-
sis was significantly reduced with regular use of  topical 
Mupirocin at the insertion site. The data were positive 
for catheters with or without cuff  and for those that were 
tunneled and not tunneled (1,17). Mupirocin is an antibiotic 
that is active against gram positive organisms (18).
Motivated by the importance of  infections associ-
ated with the use of  CVC for hemodialysis, and their 
impact on the number of  hospitalizations, catheter 
changes, bacteremia and death related to infection, this 
systematic review with meta-analysis was conducted 
with support of  the Paulista School of  Nursing / 
UNIFESP and the Cochrane Collaboration in Brazil. 
The principal objectives of  this review were to evalu-
ate the impact of  the use of  topical Mupirocin at the 
insertion site of  CVC in hemodialysis, and the occur-
rence of  infectious events related to the use of  CVC 
for hemodialysis, bacteremia and bacteremia caused by 
Staphylococcus aureus. 
METHODS
This systematic review with meta-analysis followed 
the steps proposed by the Cochrane Collaboration (19) 
and used the PICO strategy, which is an acronym for: 
Patient, Intervention, Comparison and Outcomes (20). 
Studies were included regardless of  language or form 
of  publication, such as those that compared the use of  
topical Mupirocin versus other interventions in the inser-
tion of  CVC for hemodialysis.
Exclusion criteria were those articles that did not 
evaluate outcomes relevant to this research.
Strategies for identifying the studies
The relevant studies were identified using electronic 
database searches of: the Cochrane Library (including “The 
Cochrane Controlled Trials Register” contained in the “Cochrane 
Library” 2010, volume 10); PUBMED (January 1966 to 
January 2010); EMBASE (January 1985 to December 2010); 
LILACS (January 1982 to December 2010); SciELO (June 
1998 to December 2010); CINAHL(June 1981 to Decem-
ber 2010); the database available at: www.controlledtrials.
com; abstracts of  papers presented at conferences; 
review articles; systematic reviews; and, randomized 
clinical trials were identified. The main keywords in the 
search strategy were: (“mupirocin”[MeSH Terms] OR 
“mupirocin”[All Fields]) AND (“haemodialysis”[All Fields] 
OR “renal dialysis”[MeSH Terms] OR (“renal”[All Fields] 
AND “dialysis”[All Fields]) OR “renal dialysis”[All Fields] 
OR “hemodialysis”[All Fields]).
Selection of  the studies
The articles were read by two independent reviewers 
(A and B) in order to ascertain whether they fulfilled 
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the inclusion criteria. Reviewers were not blinded; they 
assessed the titles and abstracts of  identified studies 
and obtained complete photocopies of  relevant articles. 
In case of  doubt or disagreement, a third reviewer (C) 
was asked to express an opinion as to whether the study 
should or should not be included in the research.
Evaluation of  methodological quality and 
statistical analysis
Methodological quality was defined as the confidence 
that the study and its presentation within the article 
would be free of  bias (19). Thus, articles were first strati-
fied according to the type of  design and, subsequently, 
in relation to the outcome, following the Cochrane 
methodology (19). 
The Review Manager 5 (21), provided by The Cochrane 
Collaboration, was utilized for statistical analysis. For di-
chotomous variables, the odds ratio (OR) with a confidence 
interval of  95% was calculated using random and fixed 
models. For calculation of  heterogeneity, we used the 
Mantel-Haenszel chi-square and I2 index (19). 
RESULTS
After an extensive bibliographic search, we identi-
fied 161 studies from the following databases: 147 
PUBMED, 7 EMBASE, 1 LILACS, and 6 through 
manual review of  references within the studies. Dur-
ing the pre-selection, 25 studies were identified by one 
reviewer and 22 by another reviewer. The discrepancies 
were resolved by a third reviewer. Finally, three studies 
were included in this review: Sesso et al. (1), Johnson et 
al. (17), and Johnson et al. (22)
All of  the studies were evaluated and classified as low 
risk of  bias and having adequate methodological quality 
by the Cochrane reference (19). Randomization of  the 
three studies included in this review was completed by 
computer, allocation concealment was adequate and the 
analysis was based on intention to treat.
The studies of  Sesso et al., (1) and Jonhson et al. (17) 
(182 participants) included in the review compared the 
use of  mupirocin topically for catheter insertion versus 
those without intervention, namely, wound dressing with 
the standard alcoholic solution of  PVPI. And another 
study by Johnson et al. (22), compared the use of  topical 
Mupirocin versus honey (101 participants).
As shown in Figure 1, infectious complications 
related to central venous catheters were significantly 
reduced in patients using topical Mupirocin in catheter 
insertion as compared with patients without interven-
tion, (RR 0.15, 95% CI 0.05 - 0.46). There was no 
significant heterogeneity between studies (Chi2 = 0.30, 
I2 = 0%, P = 0.59).
Figure 1. Infectious complications related to the use of 
central venous catheters for hemodialysis comparing topical 
Mupirocin versus no intervention
Figure 2 shows that the occurrence of  bacteremia 
related to central venous catheters was significantly re-
duced in patients who used topical Mupirocin on catheter 
insertion compared to the patient group without the 
intervention, RR 0,11, 95% IC 0.04 -0.35. There was no 
significant heterogeneity between studies (Chi2 = 0.15, 
I2 = 0%, p=0.69). 
Figure 2. Bacteremia when comparing topical Mupirocin versus 
no intervention
Figure 3 shows that there was a significant reduction 
in bacteremia caused by S. aureus in the intervention 
group compared to the control group, RR 0,07 [0.01-
0.40]. There was no significant heterogeneity between 
studies (Chi2 = 0.00, I2 = 0%, P=0.95).
Figure 3. Bacteremia caused by S. aureus when comparing topical 
Mupirocin versus no intervention
In Figure 4, the results are shown for interventions of  
topical Mupirocin versus honey in catheter insertion, from 
a single study that assessed the occurrence of  bacteremia 
caused by S. aureus related to the use of  CVC. The data 
were not significant, (RR 1.02, 95% CI 0.06 -16.77). 
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Figure 4 – Bacteremia caused by S. Aureus, comparing topical 
Mupirocin versus honey
DISCUSSION 
The principal objective of  this study was to evaluate 
the impact of  the use of  topical Mupirocin in the inser-
tion of  CVC used for hemodialysis, and the results point 
to a significant reduction in the occurrences of  infectious 
events, bacteremias and bacteremias caused by S. Aureus. 
The methodology of  this systematic review was rigor-
ous, following the Cochrane recommendations: the whole 
process was performed by two independent reviewers, 
the search strategy was broad, and, there was no language 
restriction. Thus, each included study was assessed for 
methodological quality and for heterogeneity among the 
studies. All these steps were intended to reduce the pos-
sibility of  biases, in order to provide greater credibility 
of  the results.
After a careful search for articles in several databases, 
abstracts of  papers presented at conferences, and the 
references of  published review and systematic review 
articles, we identified 174 relevant articles. Of  these, only 
three met the criteria for inclusion in the study, which was 
that the articles must be about the use of  Mupirocin ver-
sus control (placebo or honey) in CVC for hemodialysis.
Sesso et al., (1) and Johnson et al. (17) reported similar 
results of  studies that evaluated the use of  Mupirocin 
versus no intervention, and about the protective effect 
of  Mupirocin in regard to infectious complications, 
bacteremia and bacteremia caused by S. aureus related to 
the use of  CVC.
Among those works, there were differences in the 
type of  catheter used for hemodialysis: nontunneled and 
without cuff  for patients followed by Sesso et al.; (1) tun-
neled and with cuff  in those followed by Johnson et. al (17). 
Many randomized clinical trials and reviews have clearly 
demonstrated that the use of  tunneled catheters and 
those with cuffs reduce the risks of  catheter-related sepsis 
by 44% -77% as compared to the use of  non-tunneled 
catheters and those without cuff, by reducing the risks of  
bacterial migration from the skin to the circulation and 
diminishing the formation of  biofilm (6,8,13,23). 
There was no statistically significant difference in 
regard to the use of  Mupirocin versus honey for bacte-
remias caused by S. aureus. Historically, honey was used 
for its antibacterial action, especially in wounds. But 
randomized clinical trials that have evaluated its effects 
are recent, with promising results for a therapeutic alter-
native for preventing bacterial resistance and causing few 
adverse events (24-25) .
This systematic review with metaanalysis provides 
evidence of  the beneficial effect of  the use of  Mupi-
rocin with insertion of  CVC for hemodialysis, for the 
preventative action against infectious complications 
and bacteremias for all causes including S. aureus. This 
systematic review and meta-analysis showed the benefi-
cial effect of  the use of  Mupirocin for the insertion of  
CVC for hemodialysis, and for prevention of  infectious 
complications and bacteremia, particularly those caused 
by S. aureus. One study showed that the topical use of  Mu-
pirocin at the catheter site for hemodialysis reduced the 
development of  S. aureus-related infections by 80% (26).
Some research also demonstrated the cost-benefit 
advantages related to the use of  Mupirocin at the catheter 
insertion site for hemodialysis, for significantly reduc-
ing the rates of  infection related to the catheters, also 
diminishing the costs of  medical and hospital-related 
procedures (26-27).
CONCLUSION
In terms of  a conclusion for this study and implica-
tions for clinical practice, the use of  topical Mupirocin 
is effective in reducing episodes of  infections and, espe-
cially, bacteremias related to CVC in this patient popula-
tion; it also allows longer use of  CVC without infection. 
Another striking factor was the significant reduction of  
infections caused by S. aureus, the most prevalent among 
these patients. New randomized clinical trials should be 
conducted to address this issue, given the scarcity of  
studies in the area.
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